Assessment of Anti-M3R antibody in patients with oral lichen planus complaining of xerostomia: a preliminary study Authors: Farzaneh Agha-Hosseini, Maryam Tahmasebinasab, Maryam Koopaie Published: 2026 ABSTRACT AbstractObjectiveOral lichen planus (OLP) is a chronic inflammatory disorder mediated by cellular immunity. Xerostomia is not a typical feature but has been reported by a subset of patients and may reflect underlying salivary gland alterations. The mechanisms contributing to xerostomia in OLP remain unclear. This study evaluated the levels of autoantibodies against the muscarinic M3 receptor (anti-M3R Ab) in the labial minor salivary glands, saliva, and serum of OLP patients with xerostomia and compared them with those of healthy controls.MethodsIn this case-control study, unstimulated whole saliva, serum samples, and labial minor salivary gland biopsies were obtained from 35 patients with OLP and xerostomia and 25 healthy controls. Anti-M3R Ab levels were measured using enzyme-linked immunosorbent assay (ELISA). Statistical analyses included Mann-Whitney U test, Spearman correlation coefficients, and multiple logistic regression.ResultsAnti-M3R Ab levels were significantly reduced in minor salivary gland tissue of OLP patients compared with controls. Lower anti-M3R Ab levels in minor salivary glands were statistically associated with higher xerostomia scores and lower unstimulated salivary flow rates. Correlation analyses showed a significant inverse relationship between glandular anti-M3R Ab levels and xerostomia severity.ConclusionsThe reduction of anti-M3R Ab within minor salivary gland tissue may represent a localized immunological alteration contributing to xerostomia in OLP. These findings underscore the importance of localized, rather than systemic, immune mechanisms in the salivary gland dysfunction observed in OLP.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12903-026-08926-y.Keywords: Oral lichen planus, Xerostomia, Muscarinic M3 receptor, Autoantibodies, Salivary glands, Immunopathology Background Oral lichen planus (OLP) is a chronic, mucocutaneous inflammatory disorder that is relatively common. Although humoral immune mechanisms may contribute to the disease process, cell-mediated immune responses are considered the primary pathogenic mechanism in OLP [1, 2]. Its prevalence ranges from 0.5% to 2.2% in the general population, typically manifesting between the third and sixth decades of life, with a marked predilection for females [3, 4]. The precise pathogenesis of OLP remains unclear [1, 5]. Nevertheless, evidence indicates that an immune response is triggered by antigenic stimulation of the mucosa through a multifaceted interaction among innate immune cells, Langerhans cells, dendritic cells, and basal keratinocytes [6, 7]. Subsequently, CD4 + T cells, through major histocompatibility complex class II (MHC II), and CD8 + cytotoxic T cells via MHC I are activated in response to keratinocytes in the basal layer [8], leading to basal keratinocyte apoptosis through intricate mechanisms involving tumor necrosis factor-alpha (TNF-α), granzymes, or Fas-Fas ligand interactions [9, 10]. As a result of keratinocyte damage, antigen presentation via MHC I and II is re-established, promoting clonal expansion of antigen-specific T cells [11–13]. The presence of a complex cellular immune network throughout the disease course is further supported by recent findings highlighting the involvement of additional Th subsets, such as Th17 and regulatory T cells (Tregs), as well as humoral immunity [14–17]. This immune mechanism may potentially lead to the manifestation of additional clinical symptoms in these patients. Salivary glands can be affected by various systemic diseases, leading to xerostomia [18], including autoimmune diseases [19], diabetes mellitus [20, 21], end-stage renal disease (ESRD) [22], and graft-versus-host disease (GVHD) [23, 24]. Furthermore, xerostomia, defined as a subjective sensation of oral dryness often accompanied by viscous saliva during clinical assessment, has been reported in a subset of individuals with OLP, and some studies suggest that up to half of patients may report symptoms of oral dryness [25, 26]. In addition, immune-mediated alterations involving the salivary glands, sometimes described as autoimmune-like sialadenitis, have been reported in some patients with OLP and may contribute to salivary gland dysfunction and symptoms of oral dryness [26]. Previous studies have reported elevated levels of salivary immunoglobulins, particularly immunoglobulin A (IgA) and immunoglobulin G (IgG), in patients with OLP compared with healthy controls, reflecting local immune activation within the oral mucosa [27, 28]. Both salivary secretion and the perception of xerostomia are governed by complex neurophysiological mechanisms involving the salivary glands and autonomic regulation [29]. Recent studies have examined muscarinic acetylcholine receptor M3 (M3R) expression in patients with OLP, reporting reduced detectable M3R levels in saliva alongside increased M3R expression within minor salivary gland tissues, a pattern that may reflect inflammatory remodeling and altered glandular function [30, 31]. Despite increasing evidence supporting the involvement of immune mechanisms in the pathogenesis of OLP, the specific role of anti-M3R Abs in the development of xerostomia remains poorly understood. Therefore, the present study aimed to evaluate the presence of anti-M3R Abs in unstimulated saliva, serum, and minor salivary gland tissues of patients with OLP, to compare these findings with those of healthy controls, and to further clarify the potential role of these antibodies in xerostomia associated with OLP. Methods Ethical statement This analytical case-control study was conducted in accordance with the Declaration of Helsinki and received ethical approval from the Ethics Committee of Tehran University of Medical Sciences (ethical code: IR.TUMS.DENTISTRY.REC.1402.075) [32]. After the study objectives were explained, participants provided written informed consent. The authors verify that all methods complied with the relevant guidelines and regulations. Study design and participants This study involved 35 patients diagnosed with OLP who were referred to the Department of Oral Medicine at Tehran University of Medical Sciences (Tehran, Iran) from June to December 2023. A control group of 25 healthy individuals without OLP lesions was randomly selected from individuals referred to the Department of Oral Medicine at Tehran University of Medical Sciences for routine oral examinations. The case and control groups were frequency matched for age and sex in order to minimize potential confounding effects of these variables on salivary parameters. The inclusion criteria included confirmation of OLP diagnosis based on two clinical criteria: bilateral reticular or papular lesions with a characteristic pattern. The diagnosis was further confirmed by three histopathological criteria: band-like infiltration of inflammatory cells in the superficial connective tissue layer (just beneath the epithelium), often predominantly T lymphocytes, hydropic degeneration of the basal epithelial layer, and the absence of dysplasia. Xerostomia was confirmed using the Lipstick and Tongue Blade tests. Xerostomia was assessed through a combination of objective methods and subjective tools (the standardized Xerostomia Inventory (XI) questionnaire, with a scoring range of 11–55 [33], as well as calculation of the Xerostomia Index, requiring a minimum of four positive responses for study inclusion) [34]. Blood tests were conducted to evaluate thyroid parameters, diabetes, iron deficiency anemia, and hepatitis. Participants’ medication histories were evaluated to exclude medication-induced xerostomia. Exclusion criteria included the presence of dysplasia in histopathology, drug-induced lichenoid reactions, use of medications affecting salivation (such as anticholinergics, antihistamines, antihypertensives, antiparkinson drugs, antiepileptics, cytotoxic agents, tranquilizers, muscle relaxants, tricyclic antidepressants), systemic diseases or syndromes including cancer, renal failure, metabolic disorders, Sjögren’s syndrome, radiotherapy history, pregnancy or lactation, smoking, alcohol consumption, heart failure, active infections, autoimmune diseases, and renal abnormalities. Considering the correlation of xerostomia with various medical conditions, including hypothyroidism, diabetes, anemia, and hepatitis, serum levels of TSH, T3, T4, CBC, SFe, Ferritin, Zinc, B12, Folate, FBS, and HCV Ab, HBV Ag, IgG1, IgG3, and IgA were assessed to exclude these conditions. Furthermore, participants’ medication histories were carefully reviewed to ensure that xerostomia was not attributable to medication use. Periodontal status was assessed, and Individuals with periodontitis, plaque-induced gingivitis, or any active dental or periodontal infection were excluded from the study. Samples of unstimulated saliva, serum, and minor salivary gland tissue were obtained from both patients with OLP and healthy controls via minor salivary gland biopsy of the lower lip. The participant enrollment process, detailing the application of inclusion and exclusion criteria for both cases and controls, is illustrated in the STROBE flow diagram (Fig. 1). This study was reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines, and the completed checklist is provided as Supplementary File 1. Participant enrollment process in the study (STROBE diagram) Saliva and serum collection and preparation Unstimulated saliva was collected between 9:00 am and 11:00 am to account for possible circadian rhythm effects on salivary composition, with participants refraining from eating or drinking for 2 h prior to sample collection. Saliva samples were collected every 30 s for 5 min into a sterile 5 mL plastic vial, following instructions for patients to remain seated allowing saliva to pool and expectorate into the vial. Thereafter, a 3 mL venous blood sample was collected from each group, and both saliva and blood samples were centrifuged at 2000 rpm for 10 min (Eppendorf 5810R centrifuge). Clear serum and saliva were then aliquoted into 2 mL microtubes without disturbing the sediment, and the tubes were stored at -20 °C. For long-term storage, samples were stored at -80 °C. Patients with xerostomia were identified using a questionnaire that required at least four positive responses [34]. Minor salivary gland tissue collection Under sterile conditions, minor salivary gland tissue from the lower lip was collected after surgical excision under local anesthesia with epinephrine (1:100000). After washing with normal saline, six tissue samples were collected and transferred to 2 mL microtubes for further processing. The samples were initially frozen in liquid nitrogen to -180 °C, then powdered, and the weight of each gland was measured accurately (Mettler Toledo-AB 204). For each 100 mg of tissue, 1 mL of solution was added. After reaching the desired volume, samples were stored at -70 °C for 24 h. Tissue homogenization was performed using an ultrasonic homogenizer (Topsonics, Iran). All samples were homogenized at -80 °C using dry ice for 7 min at 90 Watts (W), alternating 7 s of activity with 3 s of rest to prevent overheating. The homogenized samples were then centrifuged at 4000 rpm for 5 min using a microcentrifuge (Sigma 30k, UK), and the supernatant was stored at -80 °C. Determination of salivary Anti-M3 antibody levels The anti-M3R Ab levels in serum, unstimulated saliva, and minor salivary gland tissue were measured using the enzyme-linked immunosorbent assay (ELISA) kit (Human muscarinic acetylcholine receptor M3, M-AChR M3 ELISA Kit, ZB-1298-H9648, ZellBio GmbH, Germany) with the detection range of 0.32-20 ng/mL, with a sensitivity less than 0.156 ng/mL, according to the manufacturer’s protocol. The assay was performed by diluting the standard solution, 50 µL of standard solution was added to the first six wells of the ELISA plate, and adding 40 µL of saliva, serum, and tissue samples from both patients and controls to the remaining wells. Anti-M3 antibody reagent was added to the wells, followed by streptavidin-HRP solution to all 96 wells. The plate was incubated for 1 h at 37 °C, washed 4 times, and then the chromogen solution was added. The plate was incubated for 20 min at 37 °C, and a color change was observed. Finally, a stop solution was added, and the absorbance was read at 460 nm using an ELISA reader. Using spectrometer software and standard curves, the concentrations of anti-M3R Ab were calculated. All ELISA tests were performed in triplicate to ensure the accuracy and reliability of the results. Sample size calculation Based on the results of a pilot study conducted on five samples from each group, with α = 0.05 and β = 0.2, it was estimated that a minimum of 24 samples per group would be required to detect a significant difference in the mean anti-M3R Ab levels in tissue, with an effect size estimated at 100 ng/mL. Statistical analysis The statistical analysis was performed utilizing SPSS software (RRID: SCR_019962, version 22), GraphPad Prism software (RRID: SCR_002798, version 9.2.1), and G*Power software (RRID: SCR_013726, version 3.1). To compare the levels of muscarinic M3 cholinergic receptor antibodies in saliva and their association with unstimulated salivary flow rate, serum, and minor salivary gland tissue between the OLP and healthy groups, the Mann-Whitney U test was applied. Correlation analysis was performed using the Spearman correlation coefficient to assess the relationship between anti-M3R Ab levels and unstimulated salivary flow rate, serum, salivary gland tissue, xerostomia questionnaire scores, xerostomia index, and the dry weight of the salivary glands. To identify the factors and their consequences associated with xerostomia in patients with OLP, multiple logistic regression models were implemented. The results are presented as mean ± standard deviation (SD), with p-value (p) < 0.05 considered statistically significant. Selection bias was mitigated by applying stringent, pre-defined inclusion/exclusion criteria to both cohorts. Measurement and analysis bias were reduced by blinding laboratory personnel and the statistical analyzer, respectively. Results Table 1 presents the primary differences between the healthy control group (n = 25) and the OLP group (n = 35). None of the patients in the OLP group exhibited cutaneous involvement, and all had only oral lesions without associated cutaneous lichen planus. The average age of individuals in the healthy control group was 40.12 ± 13.97 years, whereas the average age of those in the OLP group was 47.03 ± 7.80 years (p = 0.018). The healthy control group consisted of 48% males and 52% females. The OLP group, on the other hand, had a greater percentage of females (77.14%) than males (22.86%). The healthy control group had salivary anti-M3R Ab levels of 2.29 ± 3.36 ng/mL, whereas the OLP group had levels of 1.72 ± 0.83 ng/mL, which was lower but not statistically significant (p = 0.368). The serum anti-M3R Ab levels were similar in the healthy controls (2.31 ± 2.08 ng/mL) and the OLP group (2.08 ± 0.82 ng/mL), with no significant difference (p = 0.331). However, the salivary gland tissue anti-M3R Ab levels were significantly lower in the OLP group (46.88 ± 92.91 ng/mL) compared to the healthy control group (145.43 ± 186.94 ng/mL, p = 0.009). The xerostomia score was significantly higher in the OLP group (4.63 ± 0.69) than in healthy controls (0.36 ± 0.57; p < 0.001). Similarly, the xerostomia index was also significantly higher in the OLP group (20.71 ± 3.26) than in the control group (11.40 ± 0.71, p < 0.001). The unstimulated salivary flow rate was significantly lower in the OLP group (0.18 ± 0.04 mL/min) compared to the healthy controls (0.43 ± 0.09 mL/min, p < 0.001). The weight of six minor salivary gland tissue samples (dried) was slightly higher in the OLP group (5.89 ± 6.91 mg) than in the healthy controls (4.58 ± 6.23 mg). However, the difference was not statistically significant (p = 0.453) (Table 1). Table 1Clinical characteristics of the healthy control group and OLP patients with xerostomiaCharacteristicsHealthy control group (n = 25)OLP patients with xerostomia(n = 35)P-value (p)Age, years *40.12 ± 13.9747.03 ± 7.800.018Sex0.051 Male12 (48.00%)8 (22.86%) Female13 (52.00%)27 (77.14%)Salivary anti-M3R Ab level (ng/mL)2.29 ± 3.361.72 ± 0.830.368Serum anti-M3R Ab level (ng/mL)2.31 ± 2.082.08 ± 0.820.331Salivary gland tissue anti-M3R Ab level (ng/mL)145.43 ± 186.9446.88 ± 92.910.009Xerostomia score0.36 ± 0.574.63 ± 0.69< 0.001Xerostomia index11.40 ± 0.7120.71 ± 3.26< 0.001Unstimulated salivary flow rate (mL/min)0.43 ± 0.090.18 ± 0.04< 0.001Weight of six salivary gland tissues, dried (mg)4.58 ± 6.235.89 ± 6.910.453* Value presented as mean ± standard deviation (SD) Clinical characteristics of the healthy control group and OLP patients with xerostomia * Value presented as mean ± standard deviation (SD) Figure 2 contrasts factors between the control and case groups. Panels A, B, and C illustrate the anti-M3R Ab levels in saliva, blood, and salivary gland tissue, respectively, with consistently elevated levels in the control group compared to patients with OLP. Panels D and E present the xerostomia index and unstimulated salivary flow rate, which are significantly different in the OLP group relative to controls (p < 0.001). Panel F shows the predicted probabilities generated by a multiple logistic regression model for each individual. A multivariable logistic regression model including age and anti-M3R Ab levels was constructed.A multivariable logistic regression analysis showed that age was significantly associated with OLP, while salivary and serum anti-M3R Ab levels were not significant (p > 0.05). However, tissue anti-M3R Ab remained independently and significantly associated with OLP after adjustment. The model demonstrated acceptable discrimination (AUC = 0.79). Comparison of variables between the case (OLP patients with xerostomia) and the healthy controls A Salivary anti-M3R Ab level (ng/mL), B Serum anti-M3R Ab level (ng/mL). C Salivary gland tissue anti-M3R Ab level (ng/mL). D Xerostomia index, E Unstimulated salivary flow rate (mL/min), and F Multiple logistic regression model using saliva, serum, salivary gland tissue anti-M3R Ab levels, and age Associations between xerostomia and related characteristics The xerostomia score exhibited a strong positive correlation with the xerostomia index in patients with OLP (r = 0.96), indicating a consistent pattern of xerostomia severity within this group. The xerostomia index was strongly correlated with xerostomia in patients with OLP (r = 0.88) compared with the healthy control group. Furthermore, a negative correlation was observed between tissue anti-M3R antibody levels and the severity of xerostomia in patients with OLP, as assessed by the xerostomia index (r = -0.33 and p = 0.037) and xerostomia score (r = -0.33 and p = 0.068). Regarding saliva and serum anti-M3R Ab, weak inverse correlations were found with the xerostomia score (r = -0.16 and r = -0.10, respectively) and the xerostomia index (r = -0.08 and r = -0.10, respectively). The unstimulated salivary flow rate showed a strong negative correlation with both the xerostomia score (r = -0.88) and the xerostomia index (r = -0.83), indicating that a reduced salivary flow rate is strongly associated with increased xerostomia severity. Age and sex were found to have weaker associations with the severity of xerostomia. Age showed moderate correlations with the xerostomia score (r = 0.46) and the xerostomia index (r = 0.38). Discussion This study presents a comparative analysis of anti-M3R Ab levels in unstimulated saliva, serum, and minor salivary gland tissues of patients with OLP presenting with xerostomia, compared with those of healthy controls. The findings provide novel insights into the immunopathogenesis of OLP-associated xerostomia, suggesting tissue-specific immune dysregulation involving the cholinergic muscarinic system. Patients with OLP exhibited significantly higher Xerostomia Inventory and Xerostomia Score values, along with a significantly lower salivary flow rate. In addition, a strong positive correlation was observed for both the Xerostomia Score (r = 0.96) and the Xerostomia Index (r = 0.88), supporting the presence of xerostomia in this patient group. It is worth noting that sex had a significant effect on unstimulated salivation, which may be related to physiological differences between males and females. Although age differed significantly between the groups, additional analyses indicated that age was not significantly associated with anti-M3R antibody levels [30, 35]. Previous studies have investigated xerostomia in patients with OLP [25, 36]; however, the underlying pathophysiological mechanisms contributing to xerostomia in OLP remain only partially understood. Several immunopathogenic mechanisms have been proposed to explain the development of xerostomia in patients with OLP, particularly involving the muscarinic M3 receptor pathway [30, 31]. One proposed mechanism involves autoantibodies with functional antagonist-like activity that interfere with acetylcholine binding to M3R, thereby reducing parasympathetic stimulation of the salivary glands [37, 38]. Another hypothesis proposes that a reduction in protective antibodies against these antagonistic autoantibodies may impair immune regulation, allowing receptor blockade to persist [6, 39]. Finally, disruptions in intracellular signaling cascades downstream of M3 receptor activation, such as those involving calcium or potassium flux, may further impair salivary secretion [37, 38]. These hypotheses, whether considered collectively or independently, underscore the complex interplay among local immune responses, receptor biology, and intracellular signaling in the pathogenesis of xerostomia in OLP. The results of the present study indicate that anti-M3R Ab levels in the minor salivary gland tissue were significantly lower in patients with OLP than in healthy control group. However, no significant differences in these levels were observed in serum and unstimulated saliva. These findings suggest a local immune response in the target tissue, which may play a crucial role in the pathogenesis of xerostomia in patients with OLP. A significant negative correlation was found between the levels of this antibody in salivary gland tissue and the dry weight of the salivary glands, as well as between tissue anti-M3R Ab levels and the xerostomia index and xerostomia score in patients with OLP, compared with the healthy control group. This finding suggests that xerostomia in OLP may not primarily result from antibody-mediated blockade of muscarinic receptors, but rather from inflammatory and functional alterations affecting the salivary glands. Smokers were excluded to minimize confounding effects on the inflammatory profile of OLP lesions. However, previous studies show that changes in the inflammatory microenvironment can influence clinical manifestations; for example, smoking has been reported to modify inflammatory infiltrates in oral lichenoid lesions [40]. Accordingly, the negative correlation between tissue anti-M3R Abs and xerostomia severity in our study may reflect inflammation-related salivary gland dysfunction rather than direct antibody-mediated receptor blockade. Regarding anti-M3R Ab levels in saliva and serum, weak inverse correlations were observed with the xerostomia score (r = -0.16 for saliva and r = -0.10 for serum) and the xerostomia index (r = -0.08 for saliva and − 0.10 for serum). These findings suggest that, although anti-M3R Ab levels in saliva and serum are associated with xerostomia severity, these associations are weaker than those observed for tissue antibody levels. This suggests that the tissue-based immune response may play a more critical role in the development of xerostomia in OLP. Furthermore, the immune mechanisms that regulate the production of autoantibodies in serum and saliva may differ from those in salivary gland tissue, leading to distinct representations of autoantibody levels in these compartments. Moreover, compensatory mechanisms in the systemic circulation or in unstimulated saliva may mask their effects [41]. Ultimately, these findings may suggest that the autoantibody response could be directed against specific peptide B-cell epitopes of the M3 receptor at the tissue level. Previous studies have reported decreased M3 receptor levels in unstimulated saliva and increased in the salivary gland tissue of patients with OLP, suggesting a compensatory response to dry mouth. These studies have also demonstrated a reduction in mucin 5B, which is important for moisturizing the oral cavity. In this study, we aim to address two key issues: first, the reduction of autoantibodies in the minor salivary glands may be due to a localized specific mechanism (rather than a systemic one). This could imply that the pathological process leading to dry mouth occurs primarily in the minor salivary glands, with less direct systemic effects in the serum and saliva [42]. Additionally, some autoantibodies in healthy individuals play a protective role against destructive autoantibodies/antagonists. An increase in these autoantibodies helps maintain function and regulate the immune response. In contrast, a reduction in these autoantibodies may lead to increased levels of inflammatory factors and destructive autoantibodies, resulting in immune dysfunction and the onset of autoimmune diseases [43]. It is possible that the destructive autoantibodies present in the minor salivary glands specifically target the unique antigens present in these glands (such as receptors, proteins, and other destructive autoantibodies). These autoantibodies may not be detectable in the blood or saliva. This tissue-specific allocation of autoantibodies could explain the reduction in M3 receptor autoantibodies [44]. The mechanisms underlying xerostomia in lichen planus are not yet fully understood. The relationship between the chronic nature of the disease and its effects on the salivary glands, as well as the resulting dry mouth sensation, remains unclear. It is unclear whether this sensation is a direct consequence of the disease or a separate, concurrent process. Exploring the underlying mechanisms and pathogenesis is essential, as it may enhance our understanding of OLP etiopathogenesis and ultimately facilitating improved management strategies and quality of life for affected individuals [45]. This study’s findings should be interpreted with its limitations in mind. The moderate sample size may have limited power to detect subtle systemic differences in anti-M3R Ab levels. While rigorous inclusion criteria were applied, the single-center recruitment strategy may limit generalizability and introduce selection bias toward more severe clinical presentations. Another limitation of the present study is the absence of a comparison group of OLP patients without xerostomia. Inclusion of such a group could have helped determine whether alterations in anti-M3R Abs are specifically associated with xerostomia in OLP patients. Furthermore, while ELISA quantified antibody levels, the functional activity (agonist/antagonist) of these autoantibodies remains uncharacterized, representing an important avenue for future research. Conclusion In conclusion, the findings of this study suggest that xerostomia in patients with oral lichen planus may be primarily associated with localized immunological alterations in the minor salivary glands rather than systemic immune changes. Although anti-M3R Ab levels in serum and saliva did not differ significantly between patients with OLP and healthy controls, a significant reduction was observed in the minor salivary gland tissues of affected patients. These results support the concept that local immune dysregulation may contribute to salivary gland dysfunction in OLP. A better understanding of these tissue-specific immune mechanisms may help guide future research and the development of targeted strategies for managing xerostomia in patients with OLP. Supplementary Information Supplementary Material 1. Acknowledgements Not applicable. Abbreviations Autoantibodies against the muscarinic M3 receptor Enzyme-linked immunosorbent assay End-stage renal disease Graft-versus-host disease Immunoglobulin A Immunoglobulin G Major histocompatibility complex class II Milliliter per minute Nanogram per milliliter Oral lichen planus Regulatory T cells Tumor necrosis factor-alpha Authors’ contributions FA-H conceived the study idea and led data collection. MT, FA-H, and MK created the study protocol and wrote the original draft. MK and MT contributed to data analysis/interpretation and to the preparation of the manuscript. MT, MK, and FA-H led the writing review and editing. All authors read and approved the final manuscript. Funding There is no source of financial support or funding. Data availability The data used and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This analytical case-control study was conducted in accordance with the Declaration of Helsinki and received ethical approval from the Ethics Committee of Tehran University of Medical Sciences (ethical code: IR.TUMS.DENTISTRY.REC.1402.075) [32]. After the study objectives were explained, participants provided written informed consent. The authors verify that all methods complied with the relevant guidelines and regulations. FA-H conceived the study idea and led data collection. MT, FA-H, and MK created the study protocol and wrote the original draft. MK and MT contributed to data analysis/interpretation and to the preparation of the manuscript. MT, MK, and FA-H led the writing review and editing. All authors read and approved the final manuscript. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The data used and/or analyzed during the current study are available from the corresponding author on reasonable request.